Atreca raises $125M in oversubscribed Series C funding round
The California-based drugmaker plans to use the money to advance its investigational drugs with MOAs based on immune system responses.
Cormorant Asset Managemet
The California-based drugmaker plans to use the money to advance its investigational drugs with MOAs based on immune system responses.